lenvatinib plus pembrolizumab

DRUG2 trials

Sponsors

Peking Union Medical College Hospital, CHA University

Conditions

Biliary Tract CancerBiomarkerCholangiocarcinomaCombinational ImmunotherapyLiver Neoplasm Malignant Primary

Phase 2

Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors

CompletedNCT03895970

Peking Union Medical College HospitalBiomarker, Cholangiocarcinoma, Combinational Immunotherapy +1

Start: 2019-04-20End: 2021-08-01Updated: 2023-03-29

Unknown Phase

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

RecruitingNCT06648057

CHA UniversityBiliary Tract Cancer, Cholangiocarcinoma

Start: 2024-09-23End: 2026-12-31Target: 100Updated: 2026-03-18

Related Papers

Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study

Frontiers in Oncology2021-11-2474 citations